Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Decreases By 5.5%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 3,420,000 shares, a decrease of 5.5% from the December 15th total of 3,620,000 shares. Based on an average daily trading volume, of 426,500 shares, the days-to-cover ratio is currently 8.0 days.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ASND. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Wedbush reiterated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Oppenheimer lowered their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. Finally, UBS Group started coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $128.13 on Monday. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $161.00. The firm’s 50 day simple moving average is $133.13 and its 200 day simple moving average is $133.47. The company has a market cap of $7.78 billion, a PE ratio of -15.86 and a beta of 0.65.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Westfield Capital Management Co. LP increased its position in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares during the period. Avoro Capital Advisors LLC raised its stake in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after buying an additional 229,995 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the last quarter. Finally, Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth about $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.